TY - JOUR
T1 - Heparin-coated bypass circuits (Carmeda) suppress the release of tissue plasminogen activator during normothermic coronary artery bypass graft surgery
AU - Spiess, B. D.
AU - Vocelka, C.
AU - Cochran, R. P.
AU - Soltow, L.
AU - Chandler, Wayne
PY - 1998/1/1
Y1 - 1998/1/1
N2 - Objectives: To study fibrinolysis in a homogenous first-time coronary artery bypass surgery (CABG) population in whom heparin-coated circuits were used. Design: A prospective, blinded, randomized, placebo-controlled study. Setting: A university hospital, tertiary care, intraoperative and postoperative intensive care unit. Participants: Twenty-one adult elective primary CABG patients. Interventions: Randomized circuit-type centrifugal pump, membrane oxygenator, rigid cardiotomy reservoir, either placebo (n = 10) or heparin-coated (n = 11) (Carmeda; Medtronic Inc., Anaheim, CA). Measurement and Main Results: Blood samples were analyzed for tissue plasminogen activator (TPA) activity, TPA antigen, plasminogen activator inhibitor-1 (PAI-1) activity, prothrombin complex F1.2, and antithrombin III (AT-III) at the following times: before cardiopulmonary bypass (CPB), during CPB (30 and 60 minutes), post-CPB, and day 1 postsurgery. TPA activity and antigen increased fivefold in the placebo group during CPB, whereas it did not even double in the heparin-coated group. PAI-1, F1.2, and AT-III were not different between groups. Conclusions: Heparin-coated CPB circuits reduced TPA release in this homogenous CABG population with routine heparin/protamine management.
AB - Objectives: To study fibrinolysis in a homogenous first-time coronary artery bypass surgery (CABG) population in whom heparin-coated circuits were used. Design: A prospective, blinded, randomized, placebo-controlled study. Setting: A university hospital, tertiary care, intraoperative and postoperative intensive care unit. Participants: Twenty-one adult elective primary CABG patients. Interventions: Randomized circuit-type centrifugal pump, membrane oxygenator, rigid cardiotomy reservoir, either placebo (n = 10) or heparin-coated (n = 11) (Carmeda; Medtronic Inc., Anaheim, CA). Measurement and Main Results: Blood samples were analyzed for tissue plasminogen activator (TPA) activity, TPA antigen, plasminogen activator inhibitor-1 (PAI-1) activity, prothrombin complex F1.2, and antithrombin III (AT-III) at the following times: before cardiopulmonary bypass (CPB), during CPB (30 and 60 minutes), post-CPB, and day 1 postsurgery. TPA activity and antigen increased fivefold in the placebo group during CPB, whereas it did not even double in the heparin-coated group. PAI-1, F1.2, and AT-III were not different between groups. Conclusions: Heparin-coated CPB circuits reduced TPA release in this homogenous CABG population with routine heparin/protamine management.
KW - Cardiopulmonary bypass
KW - Coagulation
KW - Coronary artery bypass graft surgery
KW - Fibrinolysis
KW - Heparin-coated circuit
KW - Tissue plasminogen activator
UR - http://www.scopus.com/inward/record.url?scp=0031865285&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031865285&partnerID=8YFLogxK
U2 - 10.1016/S1053-0770(98)90010-6
DO - 10.1016/S1053-0770(98)90010-6
M3 - Article
C2 - 9636912
AN - SCOPUS:0031865285
VL - 12
SP - 299
EP - 304
JO - Journal of Cardiothoracic and Vascular Anesthesia
JF - Journal of Cardiothoracic and Vascular Anesthesia
SN - 1053-0770
IS - 3
ER -